• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $HLVX

    HilleVax Inc.

    Subscribe to $HLVX
    $HLVX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

    IPO Year: 2022

    Exchange: NASDAQ

    Website: https://www.hillevax.com

    Recent Analyst Ratings for HilleVax Inc.

    DatePrice TargetRatingAnalyst
    7/9/2024$28.00 → $2.00Outperform → Market Perform
    Leerink Partners
    7/9/2024$34.00 → $3.00Buy → Hold
    Stifel
    7/9/2024$28.00 → $2.00Buy → Neutral
    H.C. Wainwright
    7/8/2024Buy → Neutral
    Guggenheim
    7/8/2024$24.00 → $5.00Overweight → Neutral
    JP Morgan
    12/13/2023$28.00Buy
    H.C. Wainwright
    See more ratings

    HilleVax Inc. Financials

    Live finance-specific insights

    See more
    • HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

      BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion. Fireside chat details:Date:  Tuesday, September 6, 2022Time:  1:00 – 2:00 p.m. Eastern Daylight Time (EDT)Moderator:  Eric Joseph, Ph.D.HilleVax Participant:  Robert Hershberg, M.D., Ph.D.,

      9/1/22 5:18:14 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    HilleVax Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gerberding Julie L.

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:12 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chu Shelley

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:15 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Hilleman Jeryl L

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:11 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Cocero Nanette

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:13 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sepulveda Jaime

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:09 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Heron Patrick J

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/30/25 7:00:05 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Maltbie Shane sold $15,117 worth of shares (8,291 units at $1.82), decreasing direct ownership by 9% to 79,887 units (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      2/12/25 4:05:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Hershberg Robert sold $48,661 worth of shares (26,535 units at $1.83), decreasing direct ownership by 2% to 1,101,498 units (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      2/12/25 4:05:07 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Frazier Life Sciences X, L.P. (Amendment)

      4/A - HilleVax, Inc. (0001888012) (Issuer)

      5/31/24 4:57:39 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kohli Aditya sold $266,291 worth of shares (18,000 units at $14.79), decreasing direct ownership by 2% to 764,878 units (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      5/22/24 5:40:39 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    HilleVax Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Frazier Life Sciences X, L.P. bought $128,325 worth of shares (8,850 units at $14.50) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/8/24 4:22:13 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcloughlin Sean bought $21,225 worth of shares (1,250 units at $16.98) (SEC Form 4)

      4 - HilleVax, Inc. (0001888012) (Issuer)

      4/1/24 4:08:42 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    HilleVax Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:10:20 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      5/8/25 7:05:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by HilleVax Inc.

      SCHEDULE 13D - HilleVax, Inc. (0001888012) (Subject)

      5/2/25 4:15:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by HilleVax Inc.

      DEF 14A - HilleVax, Inc. (0001888012) (Filer)

      4/30/25 7:40:10 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by HilleVax Inc.

      DEFA14A - HilleVax, Inc. (0001888012) (Filer)

      4/30/25 7:35:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by HilleVax Inc.

      10-K - HilleVax, Inc. (0001888012) (Filer)

      3/28/25 5:10:22 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      3/28/25 5:05:08 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - HilleVax, Inc. (0001888012) (Filer)

      12/5/24 4:05:09 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by HilleVax Inc.

      10-Q - HilleVax, Inc. (0001888012) (Filer)

      11/7/24 8:10:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HilleVax, Inc. (0001888012) (Filer)

      11/7/24 8:05:09 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    HilleVax Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    HilleVax Inc. Leadership Updates

    Live Leadership Updates

    See more

    HilleVax Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    HilleVax Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HilleVax downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded HilleVax from Outperform to Market Perform and set a new price target of $2.00 from $28.00 previously

      7/9/24 9:48:14 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Stifel with a new price target

      Stifel downgraded HilleVax from Buy to Hold and set a new price target of $3.00 from $34.00 previously

      7/9/24 7:46:22 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded HilleVax from Buy to Neutral and set a new price target of $2.00 from $28.00 previously

      7/9/24 7:46:01 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by Guggenheim

      Guggenheim downgraded HilleVax from Buy to Neutral

      7/8/24 12:10:50 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax downgraded by JP Morgan with a new price target

      JP Morgan downgraded HilleVax from Overweight to Neutral and set a new price target of $5.00 from $24.00 previously

      7/8/24 10:24:51 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on HilleVax with a new price target

      H.C. Wainwright initiated coverage of HilleVax with a rating of Buy and set a new price target of $28.00

      12/13/23 7:42:57 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

      BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connection with Mr. McLoughlin's appointment, Co-founder and current Chief Operating Officer Dr. Aditya Kohli will remain a full-time executive with the company as Chief Business Officer, where he will be responsible for business development and corporate strategy.  Mr. McLoughlin has three decades of commercial and operational experience in vaccines, most recently as the Global Vaccine Commercialization Le

      1/18/24 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

      BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "HilleVax has continued to make excellent progress in our HIL-214 program following completion of enrollment of our NEST-IN1 clinical trial in late April 2023. Due to issues relating solely to the logistical complexity of pr

      8/14/23 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

      BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "HilleVax has continued to make excellent progress on our HIL-214 program, including the recent completion of enrollment of over 3,000 subjects in our NEST-IN1 clinical trial," said Rob Hershberg, MD, PhD, Chairman and Chief

      5/12/23 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

      BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Nanette Cocero, Ph.D., MBA, to its Board of Directors, effective May 8, 2023. Dr. Cocero served as the Global President of Pfizer Vaccines during the last four years and is a recognized leader in global healthcare. "I am pleased to welcome Nanette, a highly respected and experienced leader in vaccines, as an independent director to the HilleVax board" said Rob Hershberg, MD, PhD, Chairman and Chief Executive Officer of HilleVax. "Nanette brings extensive experience in development and d

      5/9/23 7:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:36:33 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by HilleVax Inc.

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      11/14/24 9:00:08 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      7/22/24 9:02:05 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by HilleVax Inc. (Amendment)

      SC 13D/A - HilleVax, Inc. (0001888012) (Subject)

      5/31/24 2:00:58 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      2/14/24 6:46:10 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      2/14/24 5:01:30 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      2/14/24 8:45:49 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      2/12/24 5:27:08 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by HilleVax Inc. (Amendment)

      SC 13G/A - HilleVax, Inc. (0001888012) (Subject)

      2/12/24 4:31:58 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by HilleVax Inc.

      SC 13G - HilleVax, Inc. (0001888012) (Subject)

      9/29/23 4:15:24 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

      $159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic alternatives BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2025. First Quarter Financial Results As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and

      5/8/25 7:00:30 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Frazier Life Sciences Appoints Aditya Kohli to Partner

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. Since joining FLS in 2016, Dr. Kohli has played a foundational role in company creation, co-founding six life sciences companies, including HilleVax (NASDAQ:HLVX, IPO in 2022)), Phathom Pharmaceuticals (NASDAQ:PHAT, IPO in 2019)), and Scout Bio (acquired by Ceva Santé Animale). He previously acted as Chief Business Officer at Phathom, Chief Operating Officer at HilleVax, and served on the Board of Scout Bio. He currently serves on the Board of HilleVax. "Aditya has been a valued member of the FLS team, and we are thrilled to se

      4/17/25 8:00:00 AM ET
      $HLVX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

      $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 mi

      3/28/25 5:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

      $189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results As of September 30, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling

      11/7/24 8:00:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

      $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2024 and highlighted recent progress. Recent Business Highlights In Q3 2024, HilleVax announced that the NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints and that the company would discontinue further develo

      8/8/24 7:20:24 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Announces Reduction in Force

      BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a workforce reduction to reduce its operating expenses. The reduction of approximately 41 employees, or approximately 40% of the company's workforce, is intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates. About HilleVaxHilleVax is a clinical-stage biopharmaceutical company focused on developing a

      7/31/24 4:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants

      The NEST-IN1 clinical study did not meet its primary or secondary efficacy endpoints, and the company will discontinue further development of HIL-214 in infants The company is exploring the potential for continued development of HIL-214 and HIL-216 in adults BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced topline data results from NEST-IN1. NEST-IN1 is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of HIL-214 in infants of approximately 5 months of age at the time of i

      7/8/24 7:30:00 AM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended March 31, 2024, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis. "We are excited to remain on track to r

      5/9/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

      Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 Enrollment for NEST-IN1 study completed in Q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of December 31, 2023 BOSTON, March 20, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2023, highlighted recent progress and outlined key upcoming milestones for HIL-214, the company's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-re

      3/20/24 4:00:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

      BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST.  HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.    Fireside chat details:  Date: Wednesday, February 7, 2024 Time: 2:00 – 2:25 p.m. Eastern Standard Time (EST)Moderator: Se

      2/5/24 4:05:00 PM ET
      $HLVX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care